Filtered By:
Drug: Aspirin
This page shows you your search results in order of date. This is page number 4.
Order by Relevance | Date
Total 5471 results found since Jan 2013.
Aspirin for those at high risk: when to stop?
BJOG. 2023 Sep 3. doi: 10.1111/1471-0528.17644. Online ahead of print.NO ABSTRACTPMID:37661295 | DOI:10.1111/1471-0528.17644
Source: BJOG : An International Journal of Obstetrics and Gynaecology - September 4, 2023 Category: OBGYN Authors: David Wright Kypros H Nicolaides Source Type: research
Effect of aspirin on incidence, recurrence, and mortality in prostate cancer patients: integrating evidence from randomized controlled trials and real-world studies
CONCLUSIONS: This meta-analysis revealed an independent correlation between the use of aspirin and reductions in both the incidence and mortality rates of PCa. However, randomized controlled trials did not find any association between aspirin use and PCa. Furthermore, the impact of aspirin on PCa occurrence was found to be dependent on both dosage and duration.PMID:37648741 | DOI:10.1007/s00228-023-03556-7
Source: Clinical Prostate Cancer - August 30, 2023 Category: Cancer & Oncology Authors: Shaodi Ma Weihang Xia Birong Wu Chenyu Sun Yuemeng Jiang Haixia Liu Scott Lowe Zhen Zhou Peng Xie Juan Gao Linya Feng Xianwei Guo Guangbo Qu Yehuan Sun Source Type: research
Antithrombotic Treatment in Coronary Artery Disease
Curr Pharm Des. 2023 Aug 30. doi: 10.2174/1381612829666230830105750. Online ahead of print.ABSTRACTCoronary artery disease exhibits a growing mortality and morbidity worldwide despite the advances in pharmacotherapy and coronary intervention. Coronary artery disease is classified as the acute coronary syndromes and chronic coronary syndromes according to the most recent guidelines of the European Society of Cardiology. Antithrombotic treatment is the cornerstone of therapy in coronary artery disease due to the involvement of atherothrombosis in the pathophysiology of the disease. Administration of antiplatelet agents, anti...
Source: Current Pharmaceutical Design - August 30, 2023 Category: Drugs & Pharmacology Authors: Gerasimos Siasos Vasiliki Tsigkou Evanthia Bletsa Panagiota K Stampouloglou Evangelos Oikonomou Konstantinos Kalogeras Ourania Katsarou Theodoros Pesiridis Manolis Vavuranakis Dimitris Tousoulis Source Type: research
Effect of aspirin on incidence, recurrence, and mortality in prostate cancer patients: integrating evidence from randomized controlled trials and real-world studies
CONCLUSIONS: This meta-analysis revealed an independent correlation between the use of aspirin and reductions in both the incidence and mortality rates of PCa. However, randomized controlled trials did not find any association between aspirin use and PCa. Furthermore, the impact of aspirin on PCa occurrence was found to be dependent on both dosage and duration.PMID:37648741 | DOI:10.1007/s00228-023-03556-7
Source: Clinical Prostate Cancer - August 30, 2023 Category: Cancer & Oncology Authors: Shaodi Ma Weihang Xia Birong Wu Chenyu Sun Yuemeng Jiang Haixia Liu Scott Lowe Zhen Zhou Peng Xie Juan Gao Linya Feng Xianwei Guo Guangbo Qu Yehuan Sun Source Type: research
Novel Anti-Inflammatory Therapies in Coronary Artery Disease and Acute Coronary Syndromes
Life (Basel). 2023 Jul 31;13(8):1669. doi: 10.3390/life13081669.ABSTRACTEvidence suggests that inflammation plays an important role in atherosclerosis and the consequent clinical presentation, including stable coronary artery disease (CAD) and acute coronary syndromes (ACS). The most essential elements are cytokines, proteins with hormone-like properties that are produced by the immune cells, endothelial cells, platelets, fibroblasts, and some stromal cells. Interleukins (IL-1β and IL-6), chemokines, interferon-γ (IFN-γ), and tumor necrosis factor-alpha (TNF-α) are the cytokines commonly associated with endothelial dys...
Source: Atherosclerosis - August 26, 2023 Category: Cardiology Authors: Yannis Dimitroglou Constantina Aggeli Panagiotis Theofilis Panagiotis Tsioufis Evangelos Oikonomou Christos Chasikidis Konstantinos Tsioufis Dimitris Tousoulis Source Type: research
Dual Antiplatelet Therapy or Antiplatelet Plus Anticoagulant Therapy in Patients with Peripheral and Chronic Coronary Artery Disease: An Updated Review
J Clin Med. 2023 Aug 14;12(16):5284. doi: 10.3390/jcm12165284.ABSTRACTDespite evidence-based therapies, patients presenting with atherosclerosis involving more than one vascular bed, such as those with peripheral artery disease (PAD) and concomitant coronary artery disease (CAD), constitute a particularly vulnerable group characterized by enhanced residual long-term risk for major adverse cardiac events (MACE), as well as major adverse limb events (MALE). The latter are progressively emerging as a difficult outcome to target, being correlated with increased mortality. Antithrombotic therapy is the mainstay of secondary pre...
Source: Atherosclerosis - August 26, 2023 Category: Cardiology Authors: Giulia Magnani Andrea Denegri Filippo Luca Gurgoglione Federico Barocelli Elia Indrigo Davide Catellani Gianluca Signoretta Alberto Bettella Domenico Tuttolomondo Emilia Solinas Francesco Nicolini Giampaolo Niccoli Diego Ardissino Source Type: research
Novel Anti-Inflammatory Therapies in Coronary Artery Disease and Acute Coronary Syndromes
Life (Basel). 2023 Jul 31;13(8):1669. doi: 10.3390/life13081669.ABSTRACTEvidence suggests that inflammation plays an important role in atherosclerosis and the consequent clinical presentation, including stable coronary artery disease (CAD) and acute coronary syndromes (ACS). The most essential elements are cytokines, proteins with hormone-like properties that are produced by the immune cells, endothelial cells, platelets, fibroblasts, and some stromal cells. Interleukins (IL-1β and IL-6), chemokines, interferon-γ (IFN-γ), and tumor necrosis factor-alpha (TNF-α) are the cytokines commonly associated with endothelial dys...
Source: Atherosclerosis - August 26, 2023 Category: Cardiology Authors: Yannis Dimitroglou Constantina Aggeli Panagiotis Theofilis Panagiotis Tsioufis Evangelos Oikonomou Christos Chasikidis Konstantinos Tsioufis Dimitris Tousoulis Source Type: research
Dual Antiplatelet Therapy or Antiplatelet Plus Anticoagulant Therapy in Patients with Peripheral and Chronic Coronary Artery Disease: An Updated Review
J Clin Med. 2023 Aug 14;12(16):5284. doi: 10.3390/jcm12165284.ABSTRACTDespite evidence-based therapies, patients presenting with atherosclerosis involving more than one vascular bed, such as those with peripheral artery disease (PAD) and concomitant coronary artery disease (CAD), constitute a particularly vulnerable group characterized by enhanced residual long-term risk for major adverse cardiac events (MACE), as well as major adverse limb events (MALE). The latter are progressively emerging as a difficult outcome to target, being correlated with increased mortality. Antithrombotic therapy is the mainstay of secondary pre...
Source: Atherosclerosis - August 26, 2023 Category: Cardiology Authors: Giulia Magnani Andrea Denegri Filippo Luca Gurgoglione Federico Barocelli Elia Indrigo Davide Catellani Gianluca Signoretta Alberto Bettella Domenico Tuttolomondo Emilia Solinas Francesco Nicolini Giampaolo Niccoli Diego Ardissino Source Type: research
Letter to Editor regarding article, "Thirty day low-dose versus regular-dose aspirin for venous thromboembolism prophylaxis in primary total joint arthroplasty"
J Orthop Surg (Hong Kong). 2023 May-Aug;31(2):10225536231198766. doi: 10.1177/10225536231198766.NO ABSTRACTPMID:37608521 | DOI:10.1177/10225536231198766
Source: Journal of Orthopaedic Surgery - August 23, 2023 Category: Orthopaedics Authors: Sheng Zhao Caining Wen Yuanmin Zhang Source Type: research
CYP2C19 Loss-of-Function Variants Associated with Long-term Ischemic Stroke Events During Clopidogrel Treatment in the Chinese Population
This study aims to determine whether CYP2C19 loss-of-function (LoF) variants were associated with long-term ischemic stroke risk in Chinese primary care patients treated with clopidogrel. Patients treated with clopidogrel were ascertained from a Chinese Electronic Medical Record linked with biobank for a retrospective cohort study. Their medical information was examined for the period from January 2018 to December 2021. Two CYP2C19 major loss of function variants (*2:rs4244285, *3: rs4986893) were genotyped. The clinical outcome was ischemic stroke event. Cox regression analysis was used to evaluate the association between...
Source: Clinical Pharmacology and Therapeutics - August 22, 2023 Category: Drugs & Pharmacology Authors: Peng Wu Ziqing Liu Zijian Tian Benrui Wu Jian Shao Qian Li Zhaoxu Geng Ying Pan Ke Lu Qiang Wang Tao Xu Kaixin Zhou Source Type: research
Berberine and aspirin prevent traumatic heterotopic ossification by inhibition of BMP signalling pathway and osteogenic differentiation
J Cell Mol Med. 2023 Aug 22. doi: 10.1111/jcmm.17919. Online ahead of print.ABSTRACTHeterotopic ossification (HO) is a pathological process that often occurs in soft tissues following severe trauma. There is no effective therapy for HO. The BMP signalling pathway plays an essential role in the pathogenesis of HO. Our previous study showed that AMPK negatively regulates the BMP signalling pathway and osteogenic differentiation. The present study aims to study the effect of two AMPK activators berberine and aspirin on osteogenic differentiation and HO induced by traumatic injury. The effects of two AMPK activators, berberine...
Source: Molecular Medicine - August 22, 2023 Category: Molecular Biology Authors: Jingjing Fan Jiayu Gao Jie Chen Jia Hou Mengchao Liu Yanmiao Dang Hui Lin Source Type: research
